Over the past three decades, life sciences companies have used their biological and chemical know-how to create significant value for themselves, their shareholders and most importantly patients. In today’s fast-changing environment, it’s very likely that life sciences companies will need access to an array of medical and non-medical data to demonstrate value to their stakeholders. In the latest 2019 EY M&A Firepower report, we explore the dealmaking strategies life sciences should prioritize to generate growth. This year’s findings show that life sciences companies must accelerate their agendas on the creation of focused business models and the acquisition of disruptive, digital capabilities.

Learn more by visiting us at ey.com/firepower

Additional audiobook formats include ​iTunes | Google Play Music | Spotify​